A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: A one-year mirror-image study with national claim-based database in Taiwan

TY - JOUR

T1 - A cost-consequence analysis of long-acting injectable risperidone in schizophrenia

T2 - A one-year mirror-image study with national claim-based database in Taiwan

AU - Chang, Hui-Chih

AU - Tang, Chao-Hsiun

AU - Huang, Sheng-Tzu

AU - McCrone, Paul

AU - Su, Kuan-Pin

PY - 2012/6

Y1 - 2012/6

N2 - Objective: The development of long-acting atypical antipsychotics has provided a new paradigm for schizophrenia treatment. The economic effectiveness of risperidone long-acting injection (RLAI) on service costs has, however, never been studied in the real world with national claim-based database. Method: To assess the change of service utilization and costs for schizophrenia before and after RLAI treatment, we conducted this 1-year mirror-image study with Taiwanese national claimed-data. Comparison was made for service sectors (the number of visits, acute admissions and relapse events) and cost components (outpatient, inpatient, emergency, medication and non-medication costs). Results: Service uses reduced in the post-RLAI period, along with a reduction of 34% and 32% on total inpatient services costs and inpatient non-medication costs, respectively (p < 0.005). However, overall psychiatric service costs went up by 26%, with an increase of 190% on total outpatient service costs and 177% on overall medication costs (p < 0.0001). Conclusions: This 1-year mirror-image analysis showed that RLAI treatment was associated with reductions of service uses; however, overall psychiatric service costs were compromised by costs incurred from increased utilization of outpatient service and RLAI medication costs under the context of healthcare in Taiwan.

AB - Objective: The development of long-acting atypical antipsychotics has provided a new paradigm for schizophrenia treatment. The economic effectiveness of risperidone long-acting injection (RLAI) on service costs has, however, never been studied in the real world with national claim-based database. Method: To assess the change of service utilization and costs for schizophrenia before and after RLAI treatment, we conducted this 1-year mirror-image study with Taiwanese national claimed-data. Comparison was made for service sectors (the number of visits, acute admissions and relapse events) and cost components (outpatient, inpatient, emergency, medication and non-medication costs). Results: Service uses reduced in the post-RLAI period, along with a reduction of 34% and 32% on total inpatient services costs and inpatient non-medication costs, respectively (p < 0.005). However, overall psychiatric service costs went up by 26%, with an increase of 190% on total outpatient service costs and 177% on overall medication costs (p < 0.0001). Conclusions: This 1-year mirror-image analysis showed that RLAI treatment was associated with reductions of service uses; however, overall psychiatric service costs were compromised by costs incurred from increased utilization of outpatient service and RLAI medication costs under the context of healthcare in Taiwan.

KW - Antipsychotics

KW - Mirror-image study

KW - Service costs

KW - Relapse Psychiatric Inpatients Medical Claims Data (PIMC)

KW - RESOURCE UTILIZATION

KW - INJECTION

KW - RELAPSE

KW - CARE

KW - NONADHERENCE

KW - RISK

U2 - 10.1016/j.jpsychires.2012.02.019

DO - 10.1016/j.jpsychires.2012.02.019

M3 - Article

SN - 0022-3956

VL - 46

SP - 751

EP - 756

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

IS - 6

M1 - N/A

ER -